What is Claimed:

1. A method of preparing a stable formulation of an ACE inhibitor which comprises the steps of:

dispersing or dissolving a metal compound in an alcohol to form a metallic alcoholic dispersion;

mixing said ACE inhibitor into said metallic alcoholic dispersion; and mixing until a clear solution is attained.

- 2. The method of claim 1 wherein said alcohol comprises ethanol and water.
- 3. The method of claim 1 wherein said ACE inhibitor is quinapril hydrochloride.
- 4. The method of claim 1 wherein said metal compound comprises sodium bicarbonate.
- 5. The method of claim 1 wherein said metal is an alkali metal.
- 6. The method of claim 1 wherein said metal is an alkali earth metal.
- 7. The method of claim 1 further comprising adding at least one excipient to said clear solution.
- 8. The method of claim 7 further comprising adding an antioxidant to said clear solution.
- 9. The method of claim 8 wherein said antioxidant is selected from the group consisting of butyl hydroxyl anisol, butyl hydroxyl toluene, maleic acid, and ascorbic acid.
- 10. The method of claim 7 wherein said excipient comprises microcrystalline cellulose, sodium starch glycolate, or combinations thereof.
- 11. A storage-stable and bio-stable formulation of ACE inhibitor comprising less than 5% by weight of hydrolytic breakdown products and having a bio/storage stability ratio of less than about 3.5.
- 12. The formulation of claim 11 wherein said bio/storage stability ratio is less than 2.

13. The formulation of claim 12 wherein said bio/storage stability ratio is less than 1.

- 14. The formulation of claim 11 wherein said ACE inhibitor comprises quinapril hydrochloride.
- 15. The formulation of claim 11 wherein said ACE inhibitor comprises enalapril maleate, quinapril hydrochloride, benazepril hydrochloride, moexipril hydrochloride, lisonopril hydrochloride, indopril hydrochloride, forsinopril sodium, or combinations thereof.
- 16. The formulation of claim 11 wherein said ACE inhibitor is stabilized in the presence of sodium bicarbonate.
- 17. A bio-stable pharmaceutical formulation of ACE inhibitor prepared in accordance with claim 1 comprising less than 11% by weight of hydrolytic breakdown product after incubation at 40°C and 75% relative humidity for 10 days and subsequent contact with water maintained at 37°C for 3 hours.
- 18. The formulation of claim 17 comprising less than 8% by weight of hydrolytic breakdown product.
- 19. The formulation of claim 18 comprising less than 5% by weight of hydrolytic breakdown product.
- 20. A bio-stable pharmaceutical formulation of ACE inhibitor prepared in accordance with claim 1 comprising less than 3.5% by weight of hydrolytic breakdown product wherein said ACE inhibitor is freshly prepared and after said freshly prepared ACE inhibitor is contacted with water maintained at 37°C for 3 hours.
- 21. The formulation of claim 20 comprising less than 2.5% by weight of hydrolytic breakdown product.
- 22. The formulation of claim 21 comprising less than 1.5% by weight of hydrolytic breakdown product.

23. A pharmaceutical preparation comprising a pharmaceutically acceptable formulation of quinapril hydrochloride substantially free of breakdown products, wherein said breakdown products comprise quinaprilat and quinapril-DKP.

- 24. The pharmaceutical preparation of claim 23 which contains less than 12.5% breakdown products by weight of said formulation after incubation at 60°C and 75% relative humidity for 10 days.
- 25. The pharmaceutical preparation of claim 24 which contains less than 6% breakdown products by weight of said formulation after incubation at 60°C and 75% relative humidity for 10 days.
- 26. The pharmaceutical preparation of claim 25 which contains less than 3% breakdown products by weight of said formulation after incubation at 60°C and 75% relative humidity for 10 days.
- 27. The pharmaceutical preparation of claim 26 which contains less than 1.5% breakdown products by weight of said formulation after incubation at 60°C and 75% relative humidity for 10 days.
- 28. The pharmaceutical preparation of claim 23 wherein said preparation is freshly prepared and which contains less than 3.5% quinaprilat by weight of said formulation after contact with water maintained at 37°C for 3 hours.
- 29. The pharmaceutical preparation of claim 28 which contains less than 2% by weight quinaprilat.
- 30. The pharmaceutical preparation of claim 29 which contains less than 1.5% by weight quinaprilat.
- 31. A method of treating a cardiovascular disorder comprising administering a storage-stable and bio-stable formulation of ACE inhibitor comprising less than 5% by weight of hydrolytic breakdown products and having a bio/storage stability ratio of less than about 3.5.

32. A method of preparing a stable formulation of quinapril hydrochloride which comprises the steps of:

dispersing or dissolving a sodium compound in an alcohol to form a metallic alcoholic dispersion;

mixing quinapril hydrochloride into said metallic alcoholic dispersion to form a metallic alcoholic and active ingredient dispersion;

mixing a thickening agent into said metallic alcoholic and active ingredient dispersion; and

mixing until a clear solution is attained.

- 33. The method of claim 32 wherein said thickening agent comprises polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, or combinations thereof.
- 34. The method of claim 32 wherein said alcohol comprises ethanol and water.
- 35. The method of claim 32 wherein said sodium compound comprises sodium bicarbonate.
- 36. The method of claim 32 further comprising adding an antioxidant to said clear solution.
- 37. The method of claim 36 wherein said antioxidant is butyl hydroxyl anisol, butyl hydroxyl toluene, maleic acid, ascorbic acid, or combinations thereof.
- 38. The method of claim 32 further comprising adding at least one excipient to said clear solution.
- 39. The method of claim 38 wherein said excipient comprises microcrystalline cellulose, sodium starch glycolate, or combinations thereof.
- 40. A storage-stable and bio-stable pharmaceutical preparation of quinapril hydrochloride prepared in accordance with claim 32.
- 41. The pharmaceutical preparation of claim 40 comprising less than 5% by weight quinaprilat and having a bio/storage stability ratio of less than about 3.5.
- 42. The pharmaceutical preparation of claim 41 wherein said bio/storage stability ratio is less than 2.

43. The pharmaceutical preparation of claim 42 wherein said bio/storage stability ratio is less than 1.

- 44. The pharmaceutical preparation of claim 40 which contains less than 12.5% breakdown products by weight of said formulation after incubation at 60°C and 75% relative humidity for 10 days.
- 45. The pharmaceutical preparation of claim 44 which contains less than 6% breakdown products by weight of said formulation after incubation at 60°C and 75% relative humidity for 10 days.
- 46. The pharmaceutical preparation of claim 45 which contains less than 3% breakdown products by weight of said formulation after incubation at 60°C and 75% relative humidity for 10 days.
- 47. The pharmaceutical preparation of claim 46 which contains less than 1.5% breakdown products by weight of said formulation after incubation at 60°C and 75% relative humidity for 10 days.
- 48. The pharmaceutical preparation of claim 40 wherein said preparation is freshly prepared and which contains less than 3.5% quinaprilat by weight of said formulation after contact with water maintained at 37°C for 3 hours.
- 49. The pharmaceutical preparation of claim 48 which contains less than 2.5% by weight quinaprilat.
- 50. The pharmaceutical preparation of claim 49 which contains less than 1.5% by weight quinaprilat.
- 51. The pharmaceutical preparation of claim 40 comprising less than 11% by weight quinaprilat after incubation at 40°C and 75% relative humidity for 10 days and subsequent contact with water maintained at 37°C for 3 hours.
- 52. The formulation of claim 51 comprising less than 8% by weight quinaprilat.
- 53. The formulation of claim 52 comprising less than 5% by weight quinaprilat.

54. A method of treating a cardiovascular disorder comprising administering quinapril hydrochloride comprising less than 5% by weight quinaprilat and having a bio/storage stability ratio of less than about 3.5.